Unfolded protein response in cancer: The Physician's perspective

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Li, Xuemei ^a   Zhang, Kezhong ^b   Li, Zihai ^c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVESPIMYCIN; BORTEZOMIB; CARFILZOMIB; CEP 18770; CHAPERONE; DRONABINOL; EEYARESTATIN 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR SUBA; EPIGALLOCATECHIN GALLATE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRESTATIN; PROTEASOME INHIBITOR; PROTEIN IRE1; PROTEIN IRE1ALPHA; PU H 71; RESVERATROL; RETASPIMYCIN; SALINOSPORAMIDE A; SNX 2112; TANESPIMYCIN; UNCLASSIFIED DRUG; VERSIPELOSTATIN; X BOX BINDING PROTEIN 1; ZEARALENONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; BREAST CARCINOMA; CARCINOGENESIS; CYTOTOXICITY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GYNECOLOGIC CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PHYSICIAN; PROGNOSIS; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID CARCINOMA; UNFOLDED PROTEIN RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 79951857650     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-8     Document Type: Review

References (118)

1. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. RJ Kaufman, Genes Dev 1999 13 1211 1233 10.1101/gad.13.10.1211 10346810 (Pubitemid 29250189)
2. The cellular response to unfolded proteins: intercompartmental signaling. DR McMillan MJ Gething J Sambrook, Curr Opin Biotechnol 1994 5 540 545 10.1016/0958-1669(94)90071-X 7765470 (Pubitemid 24321424)
3. Tripartite management of unfolded proteins in the endoplasmic reticulum. K Mori, Cell 2000 101 451 454 10.1016/S0092-8674(00)80855-7 10850487
4. Signal integration in the endoplasmic reticulum unfolded protein response. D Ron P Walter, Nat Rev Mol Cell Biol 2007 8 519 529 10.1038/nrm2199 17565364 (Pubitemid 46985379)
5. The unfolded protein response: an intracellular signalling pathway with many surprising features. C Sidrauski R Chapman P Walter, Trends Cell Biol 1998 8 245 249 10.1016/S0962-8924(98)01267-7 9695849 (Pubitemid 28243207)
6. UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators. DT WJ Rutkowski SH Back RJ Kaufman,, et al. Dev Cell 2008 15 6 829 40 10.1016/j.devcel.2008.10.015 19081072
7. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. G Wang ZQ Yang K Zhang, Am J Transl Res 2010 2 65 74 20182583
8. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. DSB Scheuner RJ Kaufman,, et al. Mol Cell 2001 7 6 1165 76 10.1016/S1097-2765(01)00265-9 11430820 (Pubitemid 32607351)
9. Increased synthesis of secreted proteins induces expression of glucose-regulated proteins in butyrate-treated Chinese hamster ovary cells. AJWL Dorner RJ Kaufman, J Biol Chem 1989 264 20602 20607 2511206 (Pubitemid 20009254)
10. The mammalian unfolded protein response. MKR Schroder, Annu Rev Biochem 2005 74 739 789 10.1146/annurev.biochem.73.011303.074134 15952902
11. Identification and characterization of endoplasmic reticulum stress-induced apoptosis in vivo. KKR Zhang, Methods Enzymol 2008 442 395 419 18662581
12. Regulation of apoptosis by the unfolded protein response. AZK Fribley RJ Kaufman, Methods Mol Biol 2009 559 191 204 19609758
13. Functional and Genomic Analyses Reveal an Essential Coordination between the Unfolded Protein Response and ER-Associated Degradation. KPC Travers L Wodicka DL Lockhart JS Weissman P Walter, Cell 2000 101 3 249 258 10.1016/S0092-8674(00)80835-1 10847680
14. One step at a time: endoplasmic reticulum-associated degradation. SSVJL Brodsky, Nature Reviews Molecular Cell Biology 2008 9 944 957 10.1038/nrm2546 19002207
15. Endoplasmic reticulum stress triggers autophagy. TNU Yorimitsu Z Yang DJ Klionsky, J Biol Chem 2006 281 40 30299 304 10.1074/jbc.M607007200 16901900 (Pubitemid 44537037)
16. Cannabinoids: potential anticancer agents. M Guzman, Nat Rev Cancer 2003 3 745 755 10.1038/nrc1188 14570037 (Pubitemid 37328813)
17. Cannabinoids and gliomas. G Velasco A Carracedo C Blazquez M Lorente T Aguado A Haro C Sanchez I Galve-Roperh M Guzman, Mol Neurobiol 2007 36 60 67 10.1007/s12035-007-0002-5 17952650 (Pubitemid 351360351)
18. Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. T Verfaillie M Salazar G Velasco P Agostinis, Int J Cell Biol 2010 930509 20145727
19. Mediators of endoplasmic reticulum stress-induced apoptosis. E Szegezdi SE Logue AM Gorman A Samali, EMBO Rep 2006 7 880 885 10.1038/sj.embor.7400779 16953201 (Pubitemid 44523966)
20. Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. P Heather YZ Harding Anne Bertolotti Zeng Huiqing Ron David, Molecular Cell 2000 5 897 904 10.1016/S1097-2765(00)80330-5 10882126
21. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. D Scheuner B Song E McEwen C Liu R Laybutt P Gillespie T Saunders S Bonner-Weir RJ Kaufman, Mol Cell 2001 7 1165 1176 10.1016/S1097-2765(01)00265-9 11430820 (Pubitemid 32607351)
22. Translational control and the unfolded protein response. RCCD Wek, Antioxid Redox Signal 2007 9 12 2357 71 2007 9 :2357-2371 10.1089/ars.2007.1764 17760508
23. Endoplasmic reticulum stress: cell life and death decisions. C Xu B Bailly-Maitre JC Reed, J Clin Invest 2005 115 2656 2664 10.1172/JCI26373 16200199 (Pubitemid 41434389)
24. From endoplasmic-reticulum stress to the inflammatory response. K Zhang RJ Kaufman, Nature 2008 454 455 462 10.1038/nature07203 18650916
25. Control of PERK eIF2alpha kinase activity by the endoplasmic reticulum stress-induced molecular chaperone P58IPK. W Yan CL Frank MJ Korth BL Sopher I Novoa D Ron MG Katze, Proc Natl Acad Sci USA 2002 99 15920 15925 10.1073/pnas.252341799 12446838 (Pubitemid 35462724)
26. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. J Ye RB Rawson R Komuro X Chen UP Dave R Prywes MS Brown JL Goldstein, Mol Cell 2000 6 1355 1364 10.1016/S1097-2765(00)00133-7 11163209 (Pubitemid 32045928)
27. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. AH Lee NN Iwakoshi LH Glimcher, Mol Cell Biol 2003 23 7448 7459 10.1128/MCB.23.21.7448-7459.2003 14559994 (Pubitemid 37271447)
28. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. KST Yamamoto T Matsui M Sato T Okada H Yoshida A Harada K Mori, Dev Cell 2007 13 365 376 10.1016/j.devcel.2007.07.018 17765680 (Pubitemid 47308680)
29. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. K Lee W Tirasophon X Shen M Michalak R Prywes T Okada H Yoshida K Mori RJ Kaufman, Genes Dev 2002 16 452 466 10.1101/gad.964702 11850408 (Pubitemid 34165102)
30. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. RV Rao DE Bredesen, Curr Opin Cell Biol 2004 16 653 662 10.1016/j.ceb.2004.09. 012 15530777 (Pubitemid 39463116)
31. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. H Yoshida T Matsui A Yamamoto T Okada K Mori, Cell 2001 107 881 891 10.1016/S0092-8674(01)00611-0 11779464 (Pubitemid 34084979)
32. Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. RV Rao S Castro-Obregon H Frankowski M Schuler V Stoka G del Rio DE Bredesen HM Ellerby, J Biol Chem 2002 277 21836 21842 10.1074/jbc.M202726200 11919205 (Pubitemid 34952336)
33. Regulation of apoptosis by endoplasmic reticulum pathways. DG Breckenridge M Germain JP Mathai M Nguyen GC Shore, Oncogene 2003 22 8608 8618 10.1038/sj.onc.1207108 14634622 (Pubitemid 38019196)
34. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. D Ron JF Habener, Genes Dev 1992 6 439 453 10.1101/gad.6.3.439 1547942
35. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. H Zinszner M Kuroda X Wang N Batchvarova RT Lightfoot H Remotti JL Stevens D Ron, Genes Dev 1998 12 982 995 10.1101/gad.12.7.982 9531536 (Pubitemid 28204605)
36. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. SJ Marciniak CY Yun S Oyadomari I Novoa Y Zhang R Jungreis K Nagata HP Harding D Ron, Genes Dev 2004 18 3066 3077 10.1101/gad.1250704 15601821 (Pubitemid 39658175)
37. The role of the unfolded protein response in tumour development: friend or foe? Y Ma LM Hendershot, Nat Rev Cancer 2004 4 966 977 10.1038/nrc1505 15573118 (Pubitemid 39626220)
38. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. TYJ Nakagawa, J Cell Biol 2000 150 887 894 10.1083/jcb.150.4.887 10953012
39. An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. N Morishima K Nakanishi H Takenouchi T Shibata Y Yasuhiko, J Biol Chem 2002 277 34287 34294 10.1074/jbc.M204973200 12097332
40. From acute ER stress to physiological roles of the Unfolded Protein Response. JKR Wu, Cell Death Differ 2006 13 3 374 84 10.1038/sj.cdd.4401840 16397578
41. Untangling the unfolded protein response. EL Davenport GJ Morgan FE Davies, Cell Cycle 2008 7 865 869 10.4161/cc.7.7.5615 18414035 (Pubitemid 351573778)
42. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. PM Fernandez SO Tabbara LK Jacobs FC Manning TN Tsangaris AM Schwartz KA Kennedy SR Patierno, Breast Cancer Res Treat 2000 59 15 26 10.1023/A:1006332011207 10752676 (Pubitemid 30153894)
43. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. DR Fels C Koumenis, Cancer Biol Ther 2006 5 723 728 16861899 (Pubitemid 44794028)
44. Mitochondria regulate the unfolded protein response leading to cancer cell survival under glucose deprivation conditions. N Haga S Saito Y Tsukumo J Sakurai A Furuno T Tsuruo A Tomida, Cancer Sci 101 1125 1132 10.1111/j.1349-7006.2010.01525.x 20210797
45. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. C Koumenis BG Wouters, Mol Cancer Res 2006 4 423 436 10.1158/1541-7786.MCR-06-0150 16849518 (Pubitemid 44197038)
46. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. L Romero-Ramirez H Cao D Nelson E Hammond AH Lee H Yoshida K Mori LH Glimcher NC Denko AJ Giaccia,, et al. Cancer Res 2004 64 5943 5947 10.1158/0008-5472.CAN-04-1606 15342372 (Pubitemid 39129389)
47. The role of X-box binding protein-1 in tumorigenicity. AN Shajahan RB Riggins R Clarke, Drug News Perspect 2009 22 241 246 10.1358/dnp.2009.22.5. 1378631 19609461
48. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. M Shuda N Kondoh N Imazeki K Tanaka T Okada K Mori A Hada M Arai T Wakatsuki O Matsubara,, et al. J Hepatol 2003 38 605 614 10.1016/S0168-8278(03)00029-1 12713871 (Pubitemid 36560645)
49. Induction of glucose-regulated protein 78 by chronic hypoxia in human gastric tumor cells through a protein kinase C-epsilon/ERK/AP-1 signaling cascade. MS Song YK Park JH Lee K Park, Cancer Res 2001 61 8322 8330 11719466 (Pubitemid 33091628)
50. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. S Sun J Han WM Ralph Jr A Chandrasekaran K Liu KJ Auborn TH Carter, Cell Stress Chaperones 2004 9 76 87 15270080 (Pubitemid 38429078)
51. Overexpression of glucose-regulated protein 94 (Grp94) in esophageal adenocarcinomas of a rat surgical model and humans. Xiaoxin Chen Yu Ding Liu Chang-Gong SM and CS Yang, Carcinogenesis 2002 23 123 130 10.1093/carcin/23.1. 123 11756233 (Pubitemid 34213561)
52. ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. J Ye C Koumenis, Curr Mol Med 2009 9 411 416 10.2174/156652409788167096 19519398
53. Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis. MG Goldstein Z Li, J Hematol Oncol 2009 2 5 10.1186/1756-8722-2-5 19183457
54. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. L Qu S Huang D Baltzis AM Rivas-Estilla O Pluquet M Hatzoglou C Koumenis Y Taya A Yoshimura AE Koromilas, Genes Dev 2004 18 261 277 10.1101/gad.1165804 14744935 (Pubitemid 38199252)
55. Biphasic, bidirectional regulation of NF-kappaB by endoplasmic reticulum stress. M Kitamura, Antioxid Redox Signal 2009 11 2353 2364 10.1089/ars.2008. 2391 19187000
56. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. C Jolly RI Morimoto, J Natl Cancer Inst 2000 92 1564 1572 10.1093/jnci/92.19.1564 11018092
57. The role of stress proteins in prostate cancer. A So B Hadaschik R Sowery M Gleave, Curr Genomics 2007 8 252 261 10.2174/138920207781386951 18645594 (Pubitemid 47240702)
58. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. D Dong M Ni J Li S Xiong W Ye JJ Virrey C Mao R Ye M Wang L Pen,, et al. Cancer Res 2008 68 498 505 10.1158/0008-5472.CAN-07-2950 18199545 (Pubitemid 351380077)
59. GRP78 induction in cancer: therapeutic and prognostic implications. AS Lee, Cancer Res 2007 67 3496 3499 10.1158/0008-5472.CAN-07-0325 17440054 (Pubitemid 46762126)
60. Stress induction of GRP78/BiP and its role in cancer. J Li AS Lee, Curr Mol Med 2006 6 45 54 10.2174/156652406775574523 16472112
61. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. FY Al-Rawashdeh P Scriven IC Cameron PV Vergani L Wyld, Eur J Gastroenterol Hepatol 22 1099 1105 10.1097/MEG.0b013e3283378405 20177386
62. GRP78 as a Novel Predictor of Responsiveness Chemotherapy in Breast Cancer. PN Eunjung Lee Darcy Spicer Susan Groshen Mimi C Yu Amy S Lee, Cancer Res 2006 66 7849 10.1158/0008-5472.CAN-06-1660 16912156
63. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Y Fu AS Lee, Cancer Biol Ther 2006 5 741 744 10.4161/cbt.5.7.2970 16861902 (Pubitemid 44775126)
64. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. H Uramoto K Sugio T Oyama S Nakata K Ono T Yoshimastu M Morita K Yasumoto, Lung Cancer 2005 49 55 62 10.1016/j.lungcan.2004.12.011 15949590 (Pubitemid 40798093)
65. Activation and clinical significance of the unfolded protein response in breast cancer. P Scriven S Coulson R Haines S Balasubramanian S Cross L Wyld, Br J Cancer 2009 101 1692 1698 10.1038/sj.bjc.6605365 19861963
66. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Q Wang Z He J Zhang Y Wang T Wang S Tong L Wang S Wang Y Chen, Cancer Detect Prev 2005 29 544 551 10.1016/j.cdp.2005.09.010 16297569 (Pubitemid 41758494)
67. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. R Langer M Feith JR Siewert HJ Wester H Hoefler, BMC Cancer 2008 8 70 10.1186/1471-2407-8- 70 18331622
68. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. HC Zheng H Takahashi XH Li T Hara S Masuda YF Guan Y Takano, Hum Pathol 2008 39 1042 1049 10.1016/j.humpath.2007.11. 009 18482745
69. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. C Jamora G Dennert AS Lee, Proc Natl Acad Sci USA 1996 93 7690 7694 10.1073/pnas.93.15.7690 8755537 (Pubitemid 26277098)
70. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. MP Davies DL Barraclough C Stewart KA Joyce RM Eccles R Barraclough PS Rudland DR Sibson, Int J Cancer 2008 123 85 88 10.1002/ijc.23479 18386815 (Pubitemid 351705195)
71. Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. BP Gomez RB Riggins AN Shajahan U Klimach A Wang AC Crawford Y Zhu A Zwart M Wang R Clarke, Faseb J 2007 21 4013 4027 10.1096/fj.06-7990com 17660348 (Pubitemid 350232358)
72. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. DR Carrasco K Sukhdeo M Protopopova R Sinha M Enos DE Carrasco M Zheng M Mani J Henderson GS Pinkus,, et al. Cancer Cell 2007 11 349 360 10.1016/j.ccr.2007.02.015 17418411 (Pubitemid 46518314)
73. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. EA Obeng LM Carlson DM Gutman WJ Harrington Jr KP Lee LH Boise, Blood 2006 107 4907 4916 10.1182/blood-2005-08-3531 16507771 (Pubitemid 43882644)
74. The potential of proteasome inhibitors in cancer therapy. JSO Sterz, Expert Opin Investig Drugs 2008 17 879 895 10.1517/13543784.17.6.879 18491989
75. Mechanism and components of endoplasmic reticulum-associated degradation. J Hoseki R Ushioda K Nagata, J Biochem 2010 147 19 25 10.1093/jb/mvp194 19923195
76. Inhibition of p97-dependent protein degradation by Eeyarestatin I. Q Wang L Li Y Ye, J Biol Chem 2008 283 7445 7454 10.1074/jbc.M708347200 18199748
77. Endoplasmic reticulum stress activates the expression of a sub-group of protein disulfide isomerase genes and AtbZIP60 modulates the response in Arabidopsis thaliana. DP Lu DA Christopher, Mol Genet Genomics 2008 280 199 210 10.1007/s00438-008-0356-z 18574595
78. Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. DM Townsend Y Manevich L He Y Xiong RR Bowers Jr S Hutchens KD Tew, Cancer Res 2009 69 7626 7634 10.1158/0008-5472.CAN-09-0493 19773442
79. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. EL Davenport HE Moore AS Dunlop SY Sharp P Workman GJ Morgan FE Davies, Blood 2007 110 2641 2649 10.1182/blood-2006-11-053728 17525289 (Pubitemid 47523188)
80. The clinical applications of heat shock protein inhibitors in cancer - present and future. U Banerji I Judson P Workman, Curr Cancer Drug Targets 2003 3 385 390 10.2174/1568009033481813 14529390 (Pubitemid 37128325)
81. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. EG Mimnaugh W Xu M Vos X Yuan JS Isaacs KS Bisht D Gius L Neckers, Mol Cancer Ther 2004 3 551 566 15141013 (Pubitemid 39193734)
82. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade. EG Mimnaugh W Xu M Vos X Yuan L Neckers, Mol Cancer Res 2006 4 667 681 10.1158/1541-7786.MCR-06-0019 16966435 (Pubitemid 44497219)
83. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. DB Solit I Osman D Polsky KS Panageas A Daud JS Goydos J Teitcher JD Wolchok FJ Germino SE Krown,, et al. Clin Cancer Res 2008 14 8302 8307 10.1158/1078-0432.CCR-08-1002 19088048
84. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. SZ Usmani RD Bona G Chiosis Z Li, J Hematol Oncol 3 40 10.1186/1756-8722-3-40 20977755
85. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. P Pyrko AH Schonthal FM Hofman TC Chen AS Lee, Cancer Res 2007 67 9809 9816 10.1158/0008-5472.CAN-07-0625 17942911 (Pubitemid 47621228)
86. Effect on tumor cells of blocking survival response to glucose deprivation. HRTA Park S Sato Y Tsukumo J Yun T Yamori Y Hayakawa T Tsuruo K Shin-ya, J Natl Cancer Inst 2004 96 17 1300 10 10.1093/jnci/djh243 15339968 (Pubitemid 39264119)
87. Preventing the unfolded protein response via aberrant activation of 4E-binding protein 1 by versipelostatin. J Matsuo Y Tsukumo J Sakurai S Tsukahara HR Park K Shin-Ya T Watanabe T Tsuruo A Tomida, Cancer Sci 2008 19068091
88. Chemical genomics identifies the unfolded protein response as a target for selective cancer cell killing during glucose deprivation. S Saito A Furuno J Sakurai A Sakamoto HR Park K Shin-Ya T Tsuruo A Tomida, Cancer Res 2009 69 4225 4234 10.1158/0008-5472.CAN-08-2689 19435925
89. Novel antitumor and neuroprotective substances discovered by characteristic screenings based on specific molecular targets. K Shin-Ya, Biosci Biotechnol Biochem 2005 69 867 872 10.1271/bbb.69.867 15914903 (Pubitemid 41006957)
90. Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. JM Backer AV Krivoshein CV Hamby J Pizzonia KS Gilbert YS Ray H Brand AW Paton JC Paton MV Backer, Neoplasia 2009 11 1165 1173 19881952
91. Irestatin, a potent inhibitor of IRE1 and the unfolded protein response, is a hypoxia-selective cytotoxin and impairs tumor growth. DFaAC Koong, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2007 25 3514
92. Trierixin, a novel Inhibitor of ER stress-induced XBP1 activation from Streptomyces sp. II. structure elucidation. Y Futamura E Tashiro N Hironiwa J Kohno M Nishio K Shindo M Imoto, J Antibiot (Tokyo) 2007 60 582 585 17917242
93. IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. J Patterson VJ Palombella C Fritz E Normant, Cancer Chemother Pharmacol 2008 61 923 932 10.1007/s00280-007-0546-0 17624530 (Pubitemid 351423119)
94. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. M Salazar A Carracedo IJ Salanueva S Hernandez-Tiedra M Lorente A Egia P Vazquez C Blazquez S Torres S Garcia,, et al. J Clin Invest 2009 119 1359 1372 10.1172/JCI37948 19425170
95. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. BQ Liu YY Gao XF Niu JS Xie X Meng Y Guan HQ Wang, Biochem Biophys Res Commun 2009 391 778 782 10.1016/j.bbrc.2009.11.137 19944671
96. Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells. R Banjerdpongchai P Kongtawelert O Khantamat C Srisomsap D Chokchaichamnankit P Subhasitanont J Svasti, J Hematol Oncol 3 50 10.1186/1756-8722-3-50 21190589
97. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. JF San Miguel R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff I Spicka MT Petrucci A Palumbo OS Samoilova,, et al. N Engl J Med 2008 359 906 917 10.1056/NEJMoa0801479 18753647
98. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. D Chauhan AV Singh B Ciccarelli PG Richardson MA Palladino KC Anderson, Blood 115 834 845 10.1182/blood-2009-03-213009 19965674
99. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. OA O'Connor AK Stewart M Vallone CJ Molineaux LA Kunkel JF Gerecitano RZ Orlowski, Clin Cancer Res 2009 15 7085 7091 19903785
100. Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies. P Lee AFW HA Burris III K Papadopoulos EA Sausville PJ Rosen DS Mendelson JR Infante A Patnaik MS Gordon, Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2010 28 8147
101. Phase II study of the proteasome inhibitor PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. G Paul BB Richardson James Berenson, Proc Am Soc Clin Oncol 2002 21 abstr 40
102. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. BR Roberto Piva Michael Williams, Blood 2008 111 5 2765 2775 10.1182/blood-2007-07-100651 18057228
103. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. PG Richardson AZ Badros S Jagannath S Tarantolo JL Wolf M Albitar D Berman M Messina KC Anderson, Br J Haematol 150 428 437 20618338
104. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. PG Richardson AA Chanan-Khan M Alsina M Albitar D Berman M Messina CS Mitsiades KC Anderson, Br J Haematol 150 438 445 20618337
105. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. EI Heath DW Hillman U Vaishampayan S Sheng F Sarkar F Harper M Gaskins HC Pitot W Tan SP Ivy,, et al. Clin Cancer Res 2008 14 7940 7946 10.1158/1078-0432.CCR-08-0221 19047126
106. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. S Pacey M Gore D Chao U Banerji J Larkin S Sarker K Owen Y Asad F Raynaud M Walton,, et al. Invest New Drugs 2010 20683637
107. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. S Kummar ME Gutierrez ER Gardner X Chen WD Figg M Zajac-Kaye M Chen SM Steinberg CA Muir MA Yancey,, et al. Eur J Cancer 46 340 347 10.1016/j.ejca.2009.10.026 19945858
108. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. JE Lancet I Gojo M Burton M Quinn SM Tighe K Kersey Z Zhong MX Albitar K Bhalla AL Hannah MR Baer, Leukemia 24 699 705 10.1038/leu.2009.292 20111068
109. Phase I pharmacokinetic and pharmacodynamic study of 17- dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. RK Ramanathan MJ Egorin C Erlichman SC Remick SS Ramalingam C Naret JL Holleran CJ TenEyck SP Ivy CP Belani, J Clin Oncol 28 1520 1526 10.1200/JCO.2009.25.0415 20177028
110. Targeting ER-Golgi homeostasis as a therapeutic strategy in lung cancer. LD V. Zismanov M Gottfried, J Clin Oncol 2010 suppl; abstr e21030
111. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent. BE Hanson DH Vesole, Expert Opin Investig Drugs 2009 18 1375 1383 10.1517/13543780903158934 19642950
112. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. E Caldas-Lopes L Cerchietti JH Ahn CC Clement AI Robles A Rodina K Moulick T Taldone A Gozman Y Guo,, et al. Proc Natl Acad Sci USA 2009 106 8368 8373 10.1073/pnas.0903392106 19416831
113. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. S Marubayashi P Koppikar T Taldone O Abdel-Wahab N West N Bhagwat E Caldas-Lopes KN Ross M Gonen A Gozman,, et al. J Clin Invest 120 3578 3593 10.1172/JCI42442 20852385
114. ntitumor activity of SNX-2112, a synthetic heat shock protein 90 inhibitor, in malignancies with amplification of the MET oncogene. MYS T. Bachleitner-Hofmann C Chen Z Zeng, J Clin Oncol 2010 28 suppl; abstr e13561
115. Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. BC Cross C McKibbin AC Callan P Roboti M Piacenti C Rabu CM Wilson R Whitehead SL Flitsch MR Pool,, et al. J Cell Sci 2009 122 4393 4400 10.1242/jcs.054494 19903691
116. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. T Luo J Wang Y Yin H Hua J Jing X Sun M Li Y Zhang Y Jiang, Breast Cancer Res 12 8 10.1186/bcr2473 20078855
117. Irestatin, a potent inhibitor of IRE1 and the unfolded protein response, is a hypoxia-selective cytotoxin and impairs tumor growth. ACK D. Feldman, Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I 2007 25 18S (June 20 Supplement) 3514 2007
118. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. M Guzman MJ Duarte C Blazquez J Ravina MC Rosa I Galve-Roperh C Sanchez G Velasco L Gonzalez-Feria, Br J Cancer 2006 95 197 203 10.1038/sj.bjc.6603236 16804518 (Pubitemid 44050919)